Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice DOI Creative Commons

Shaohong Tao,

Yu‐Qing Lei, Yimei Tan

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Oct. 8, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty disease, continues to rise with rapid economic development and poses significant challenges human health. No effective drugs are clinically approved. MASLD is regarded a multifaceted pathological process encompassing aberrant lipid metabolism, insulin resistance, inflammation, gut microbiota imbalance, apoptosis, fibrosis, cirrhosis. In recent decades, herbal medicines have gained increasing attention potential therapeutic agents for the prevention treatment of MASLD, due their good tolerance, high efficacy, low toxicity. this review, we summarize mechanisms MASLD; emphasis placed on anti-MASLD Chinese formula (CHF), especially effects improving intestinal flora, fibrosis. Our goal better understand pharmacological CHF inform research new MASLD.

Language: Английский

Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort DOI Creative Commons
Maha Elsabaawy, Madiha Naguib,

Ahmed Abuamer

et al.

Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 14, 2025

The diagnostic criteria for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Associated Steatotic (MASLD) aim to refine the classification of fatty liver diseases previously grouped under Non-Alcoholic (NAFLD). This study evaluates applicability MAFLD MASLD frameworks in NAFLD patients, exploring their clinical utility identifying high-risk patients. A total 369 patients were assessed using criteria. Baseline characteristics, metabolic profiles, hepatic fibrosis, cardiovascular risks compared across groups. Among 97.55% (n = 359) met criteria, 97.01% 357) fulfilled Both captured overlapping populations, with encompassing slightly more cases. No significant differences observed risk factors, fibrosis indices (APRI, FIB-4, score), or (10-year ASCVD score). small subset lean (10 cases) distinct profiles remained uncategorized by either framework. Pure cases 10) mild insulin resistance (HOMA-IR: 3.07 ± 0.33) elevated LDL (102.5 42.87 mg/dL), while indicated low risk. Steatosis supported diagnosis early-stage preserved function. These do not meet inclusion frameworks, highlighting a gap current systems. align closely capturing MASLD-enhanced inclusivity. Further refinement is required address heterogeneity, particularly Hypertension prevalence was comparable (17.4% NAFLD, 18.2% MAFLD, 17.8% MASLD; p 0.960), as diabetes mellitus (36.7%, 37.8%, 37.6%, respectively; 0.945). Body mass index also similar groups, medians 33.25, 33.6, 33.4 kg/m2 (p 0.731). Non-invasive markers including APRI, scores, did differ significantly, median FIB-4 scores around 1.05 0.953). Similarly, results steatosis score.

Language: Английский

Citations

1
Cytokeratin 18 fragment in liver inflammation and fibrosis: Systematic review and meta-analysis DOI
Junzhao Ye,

Jiaming Lai,

Ling Luo

et al.

Clinica Chimica Acta, Journal Year: 2025, Volume and Issue: unknown, P. 120147 - 120147

Published: Jan. 1, 2025

Language: Английский

Citations

1
Feasibility of Serum Galectin-1 as a Diagnostic Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study on a Segment of the Chinese Population Using Convenience Sampling DOI Creative Commons

Ting Zeng,

Fang Li, Min Jae Yang

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 425 - 425

Published: Feb. 10, 2025

Background/Objectives: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is commonly considered as a hepatic manifestation of metabolic syndrome, posing considerable public health and economic challenges due to its high prevalence. This study investigates the diagnostic potential serum galectin-1 levels in MASLD patients. Methods: A total 128 participants were analyzed for this study, comprising 68 healthy controls 60 The steatosis index (HSI) fatty liver (FLI) calculated evaluate steatosis. Serum measured using an enzyme-linked immunosorbent assay. We additionally conducted comparative analysis mRNA protein expression tissue between mouse models MASLD, including ob/ob mice (n = 6), high-fat diet-fed C57 control group 6). Results: Average significantly differed groups, with lower values (p < 0.01). frequency increased higher quartiles correlation showed positive relationship both HSI FLI multivariate logistic regression indicated that elevated was associated risk 0.01), yielding area under receiver operating characteristic curve predicting at 0.745 (95% CI: 0.662-0.829). Hepatic also model transcript Conclusions: can be used biomarker help diagnose MASLD.

Language: Английский

Citations

0
Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis DOI
Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii

et al.

Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Language: Английский

Citations

0
The role of the advanced lung cancer inflammation index (ALI) in the risk of liver fibrosis and mortality among US adult MAFLD patients: a cross-sectional study of NHANES 1999–2018 DOI Creative Commons

Chunchun Yu,

L. Chen,

Wanting Hu

et al.

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 20, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent chronic globally, with inflammation and nutrition playing key roles in its progression. The Advanced Lung Cancer Inflammation Index (ALI) novel biomarker reflecting nutritional inflammatory status. This study aims to explore the association between ALI risk of fibrosis prognosis MAFLD patients. cross-sectional analyzed NHANES data from 1999–2018 on adult participants US. Weighted logistic regression assessed risk. Mortality outcomes, including all-cause, cardiovascular (CVD), cancer mortality, using weighted Kaplan-Meier Cox proportional hazards models. Restricted cubic splines (RCS) threshold effect analyses were uesd non-linear relationships. Receiver operating characteristic (ROC) curve evaluated prognostic value ALI, stratified examined subgroup differences. A total 6,858 patients (mean age 51.38 ± 17.22 years, 54% male) included. relationship was found risk, at 5.68, beyond which increased significantly (OR = 2.35, 95% CI: 1.89–2.95). Stronger associations observed subgroups central obesity prediabetes (P for interaction < 0.05). inversely associated all-cause mortality (HR 0.64, 0.56–0.72) CVD 0.57, 0.46–0.65), but not mortality. RCS analysis showed an L-shaped (threshold 5.36) linear Low HDL cholesterol excessive alcohol consumption influenced demonstrated highest predictive accuracy reduced highlighting potential assessing prognosis, particularly CVD-related

Language: Английский

Citations

0
MAFLD vs. MASLD: a year in review DOI

Mingqian Jiang,

Amna Subhan Butt,

Ian Homer

et al.

Expert Review of Endocrinology & Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 12

Published: April 12, 2025

In 2023, metabolic dysfunction-associated steatotic liver disease (MASLD) was introduced following fatty (MAFLD). Both aim to address the limitations of nonalcoholic (NAFLD). This review analyzes similarities and differences between MAFLD MASLD, focusing on their impacts epidemiology, diagnosis, stigma, related diseases. Current evidence suggests that criteria effectively identify individuals at higher risk through a good balance sensitivity specificity. Moreover, is more generalizable term easily understood globally. The transition from NAFLD MASLD marks significant advance in understanding within hepatology. identifies homogeneous cohort patients with due dysfunction provides valuable framework for holistic, patient-centered management strategies consider various contributing factors improve health outcomes.

Language: Английский

Citations

0
Association Between Alpha-1-Acid Glycoprotein and Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Adult Women DOI Creative Commons
Yansong Fu, Siyi Zhang, Xin Zeng

et al.

Metabolites, Journal Year: 2025, Volume and Issue: 15(4), P. 280 - 280

Published: April 17, 2025

Background: Alpha-1-acid glycoprotein (AGP) is a synthesized mainly by the liver. Nonalcoholic fatty liver disease (NAFLD) and fibrosis (LF) are associated with metabolic disorders. The aim of this study was to examine potential correlation between AGP both NAFLD LF. Methods: data were derived from 2017–2023 National Health Nutrition Examination Survey (NHANES). linear association LF examined multivariate logistic regression models. Non-linear relationships described fitting smoothed curves threshold effect analysis. Subgroup analysis also performed assess regulatory factors. Results: included 2270 females. found be significantly positively [OR = 12.00, 95% CI (6.73, 21.39), p < 0.001] 2.20, (1.07, 4.50), 0.042]. Furthermore, different in diabetic subgroup (p 0.05 for interaction). Additionally, we an inverted U-shaped relationship controlled attenuation parameter (CAP), inflection point at 1.20 g/L. Conclusions: We significant positive LF, there CAP.

Language: Английский

Citations

0
Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases DOI Open Access
Ludovico Abenavoli, Giuseppe Guido Maria Scarlata, Massimo Borelli

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2973 - 2973

Published: April 25, 2025

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in inflammatory bowel (IBD) patients due to chronic inflammation and metabolic disturbances. However, reliable non-invasive biomarkers for MASLD prediction this population are lacking. This study evaluated the predictive value of scores lipid ratios onset IBD patients. Methods: An observational retrospective was conducted on 358 at “Renato Dulbecco” Teaching Hospital Catanzaro, Italy, a period between 1 January 2021 31 December 2024. Clinical laboratory data, including ratios, were analyzed using chi-square Kruskal–Wallis tests as appropriate. Post hoc comparisons Dunn’s test. Receiver operating characteristic analysis assessed their accuracy MASLD. p < 0.05 considered significant. Results: IBD-MASLD had significantly higher body mass index (BMI, 27 ± 4 vs. 22 2 kg/m2; 0.001), waist circumference (100 11 85 cm; other anthropometric parameters, scores, than IBD-only The score insulin resistance [METS-IR, area under curve (AUC = 0.754)] 0.754) exhibited highest accuracy, followed by accumulation product (LAP, AUC 0.737), BMI 0.709), triglyceride/high-density lipoprotein (TG/HDL, 0.701). Insulin homeostasis model assessment 0.680) triglyceride-glucose 0.674), moderate use. visceral adiposity 0.664) low-density lipoprotein/high-density 0.656) showed lower discriminative ability, while fibrosis-4 0.562) weakest diagnostic performance. Conclusions: Our findings suggest that primarily driven cardiometabolic dysfunction. introduction METS-IR, LAP, TG/HDL into clinical assessments could prove useful preventing cardiovascular complications setting.

Language: Английский

Citations

0
Chitinase 3-like protein 1: a diagnostic biomarker for early liver fibrosis in autoimmune liver diseases DOI Creative Commons

S X Liu,

Cong‐Gao Peng,

Shijia Xia

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 25, 2025

Background and Aims Chitinase 3-like protein 1 (CHI3L1) is a marker of liver fibrosis produced mainly by hepatic macrophages. However, few studies have assessed the relationship between CHI3L1 in autoimmune diseases (AILDs). We aimed to explore diagnostic value for AILDs compare its application differences chronic hepatitis B (CHB) patients. Methods The fibrotic group was defined as stiffness measurement (LSM) &gt; 9.70kPa. Serum levels were measured ELISA 78 patients, 65 accuracy evaluated area under receiver operating characteristic curve (AUROC). Results patients positively correlated with LSM (r=0.750, p &lt; 0.001). AUROC serum identifying significant 0.939 (95% CI: 0.891 - 0.988), which higher than that other non invasive scores (APRI, FIB 4, GPR, AAR, NLP, PLR). At optimal cutoff 86.84 ng/mL, sensitivity specificity 92.9% 83.3%, respectively. Furthermore, no difference LSM, disease CHB group. Conclusion an effective non-invasive indicator assessing may vary different etiologies.

Language: Английский

Citations

0
MASLD: an emerging factor in the pathophysiology and clinical management of ICC DOI Open Access
Zong‐Long Li,

Jia-Lu Chen,

Yue Tang

et al.

Hepatoma Research, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 29, 2024

This article explores the emerging role of metabolic dysfunction-associated steatotic liver disease (MASLD) in pathophysiology intrahepatic cholangiocarcinoma (ICC). Despite advances public health, ICC incidence has risen, suggesting overlooked risk factors. Recent studies indicate a significant association between MASLD and ICC, though causality remains unproven. The reviews current research, highlighting limitations such as retrospective designs small sample sizes. It emphasizes need for comprehensive investigations into MASLD’s pathogenesis, prognosis, management. Future research should focus on integrating advanced methodologies to identify novel biomarkers therapeutic strategies, aiming improve patient outcomes develop tailored prevention treatment approaches.

Language: Английский

Citations

2